We are live on ! Find out more
TARS icon

Tarsus Pharmaceuticals
TARS

105 hedge funds and large institutions have $529M invested in Tarsus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

277% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 13

108% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 12

87% more call options, than puts

Call options by funds: $577K | Put options by funds: $308K

37% more capital invested

Capital invested by funds: $387M → $529M (+$142M)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

14% more funds holding

Funds holding: 92 → 105 (+13)

11.35% more ownership

Funds ownership: 79.98% → 91.33% (+11%)

Holders
105
Holders Change
+13
Holders Change %
+14.13%
% of All Funds
1.67%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
25
Increased
49
Reduced
13
Closed
12
Calls
$577K
Puts
$308K
Net Calls
+$269K
Net Calls Change
+$7K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$21.2M
2
TCM
TCG Crossover Management
California
+$20.2M
3
DM
Deerfield Management
New York
+$13.3M
4
Millennium Management
Millennium Management
New York
+$13.1M
5
IC
Ikarian Capital
Texas
+$9.18M

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$3.59M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.64M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.33M
4
AG
Algert Global
California
-$852K
5
UOC
UBS O'Connor
Illinois
-$849K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$4.34M +$4.32M +244,155 New
Northern Trust
27
Northern Trust
Illinois
$3.75M +$319K +18,007 +9%
Charles Schwab
28
Charles Schwab
California
$3.35M +$632K +35,730 +23%
Macquarie Group
29
Macquarie Group
Australia
$2.67M – – –
Bank of America
30
Bank of America
North Carolina
$2.55M +$332K +18,786 +15%
NCM
31
Nantahala Capital Management
Connecticut
$2.41M +$2.4M +135,500 New
JGC
32
J. Goldman & Co
New York
$2.24M +$1.24M +69,937 +125%
BFM
33
Boothbay Fund Management
New York
$1.99M +$1.98M +111,772 New
Renaissance Technologies
34
Renaissance Technologies
New York
$1.9M -$134K -7,600 -7%
AllianceBernstein
35
AllianceBernstein
Tennessee
$1.88M +$1.5M +85,000 +411%
N
36
Nuveen
North Carolina
$1.88M +$640K +36,139 +52%
Goldman Sachs
37
Goldman Sachs
New York
$1.78M +$409K +23,110 +30%
Point72 Asset Management
38
Point72 Asset Management
Connecticut
$1.76M +$1.76M +99,300 New
Morgan Stanley
39
Morgan Stanley
New York
$1.31M +$420K +23,738 +47%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$1.27M -$3.17K -179 -0.2%
SEI Investments
41
SEI Investments
Pennsylvania
$1.13M +$1.13M +63,613 New
Two Sigma Advisers
42
Two Sigma Advisers
New York
$1.09M +$545K +30,800 +102%
UOC
43
UBS O'Connor
Illinois
$982K -$849K -48,000 -46%
Two Sigma Investments
44
Two Sigma Investments
New York
$961K +$81.9K +4,628 +9%
GWA
45
GGM Wealth Advisors
Maryland
$953K -$265 -15 -0%
Ameriprise
46
Ameriprise
Minnesota
$947K +$662K +37,430 +236%
SG Americas Securities
47
SG Americas Securities
New York
$901K +$162K +9,141 +22%
CWM
48
CIBC World Markets
New York
$889K – – –
GCM
49
Ghisallo Capital Management
Massachusetts
$889K +$885K +50,000 New
Tudor Investment Corp
50
Tudor Investment Corp
Connecticut
$889K +$885K +50,000 New
1
2
3 4 5

TARS Hedge Fund Activity: Q3 2023 in Review

105 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2023, worth a combined $529M — up 37% from $387M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TARS positions and 12 closed out — a net gain of 13 holders — while 49 added to existing stakes and 13 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $21.2M. The largest seller was Cowen and Company, cutting an estimated $3.59M.

  • 105 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2023, up from 92 in Q2 2023.
  • Funds reported $529M of Tarsus Pharmaceuticals stock for Q3 2023, up 37% quarter-over-quarter.
  • 25 funds opened new Tarsus Pharmaceuticals positions in Q3 2023 and 12 closed out, a net change of +13 holders.
  • The largest Tarsus Pharmaceuticals buyer in Q3 2023 was Cormorant Asset Management, an estimated $21.2M added.
  • The largest Tarsus Pharmaceuticals seller in Q3 2023 was Cowen and Company, an estimated $3.59M sold.

Based on aggregated 13F filings for Q3 2023.